Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (151-160 of 212) with videos related to

Pageof 22
Sort By:
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
Pageof 22

Showing results (151-160 of 212) with videos related to

Sort By:
Pageof 22
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Cancer|October 4, 2025
Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical careLisa M Gudenkauf, Danielle B Tometich, Aasha I Hoogland, et al.
Pageof 22